



THE SEVENTH ESWI
INFLUENZA
CONFERENCE

#ESWI2020 VIRTUAL EDITION

6-9 DECEMBER 2020

European
Scientific
Working group *on*
Influenza



THE SEVENTH ESWI
INFLUENZA
CONFERENCE

#ESWI2020 VIRTUAL EDITION
6-9 DECEMBER 2020



The Organising Committee of the Seventh ESWI Influenza Conference was very excited to launch the Virtual edition of #ESWI2020.

We felt it has never been more important to connect and come together with influenza, RSV disease, COVID-19 experts and policy makers. COVID-19 has clearly shown that a previously unknown pathogen may strike at any time, in any place and without any warning. There is a clear need for countries to have the capacity to maintain effective alert and response systems to detect and quickly react to outbreaks and to share information about such outbreaks rapidly and transparently.

ESWI has been putting influenza pandemic preparedness on the agenda of society for 3 decades now. Influenza and COVID-19 clearly have overlapping pandemic preparedness strategies. Policy makers and scientists responsible for managing this raging COVID-19 pandemic have turned to historical experience with influenza pandemics and for good reason. Intervention strategies perspectives need to be addressed urgently and the clinical perspectives and pathogenesis perspectives of influenza virus, RSV and SARS-CoV-2 need to be discussed between peers and stakeholders.

We had hoped to reschedule the Seventh ESWI Influenza Conference "live version" later at the beginning of December, but in September already it became clear that large gatherings would still be prohibited and existing travel bans would still be in place, and additionally we wanted to prioritize the health and safety of our faculty and attendees. We had therefore decided to go 'virtual', and to make the 7th ESWI Influenza Conference a virtual Conference.



This was our programme:

Sunday 6 december

Sunday 6 December, 08:00 - 10:00 CET
Webinar: Influenza and RSV in a COVID-19 world

TIME:
Sunday 6 December, 08:00 - 10:00 CET

CHAIR:
Ab Osterhaus, TIHo, Hannover

1. Influenza, RSV and COVID-19: similarities and differences
Arnold Monto, University of Michigan, USA
2. Epidemiology: what if COVID-19 strikes in the flu season?
Colin Russell, University of Amsterdam, NL
3. Challenges in serology for COVID-19
Linfa Wang, Duke-NUS Medical School, SG
4. Diagnoses for influenza, RSV and COVID-19 and consequences
Marco Goeynber, Erasmus MC, NL

Sunday 6 December, 10:00 - 12:00 CET
Opening ceremony

TIME:
Sunday 6 December, 10:00 - 12:00 CET

LIVE

CHAIRS:
Ab Osterhaus, TIHo, Hannover
Colin Russell, Academic Medical Center, University of Amsterdam
Marco Goeynber, Erasmus MC

- PROGRAMME:
1. **ECDC Director Andrea Ammon's message to participants of the ESWI Influenza Conference**
Andrea Ammon, European Centre for Disease Prevention and Control, Sweden
 2. **Opening keynote lecture: The latest on the covid-19 global situation & how the pandemic spread**
Sylvie Briand, World Health Organisation, Switzerland
 3. **Opening keynote lecture: Hemagglutinin-stalk based universal influenza virus vaccines**
Florian Kramer, Icahn School of Medicine at Mount Sinai, United States of America

Sunday 6 December, 12:00 - 12:30 CET
Keynote lecture: From SARS to COVID-19, understanding the interspecies transmission of SARS-related coronaviruses

SCS KEY

TIME:
Sunday 6 December, 12:00 - 12:30 CET

TRACKS:
Scientific Programme, Keynote lectures

SPEAKER:
Zhengli Shi, Wuhan Institute of Virology

Sunday 6 December, 12:00 - 14:00 CET
How to join forces in influenza pandemic preparedness – what can we learn from COVID-19?

SPI

TIME:
Sunday 6 December, 12:00 - 14:00 CET

LIVE

TRACK:
Science Policy Interface

CHAIR:
Sylvie van der Werf, Institut Pasteur

- PROGRAMME:
1. **The vaccine R&D ecosystem after COVID-19: paradigm shifts or business as usual in tackling future influenza pandemic threats?**
Marissa D Malchione, Sabin Vaccine Institute, Washington, DC, USA
 2. **The Alliance for Influenza Preparedness: strategic priorities to enhance our global response to the next pandemic.**
Joseph Bresee, US CDC, United States of America
 3. **The threat of a new influenza pandemic: its certainty, its unpredictability (or not?), its potential magnitude and speed.**
Gülsah Gabriel, Heinrich-Pette-Institute, Leibniz Institute for Experimental Virology, Hamburg, Germany
 4. **Challenges in the supply of influenza Vaccines during the COVID-19 Pandemic and lessons learned**
Beverly Taylor, International Federation of Pharmaceutical Manufacturers and Associations, United Kingdom

Sunday 6 December, 14:00 - 14:30 CET
Keynote lecture: A shift in perspective: Understanding the patient experience of Influenza, COVID and RSV

SCS KEY

TIME:
Sunday 6 December, 14:00 - 14:30 CET

TRACKS:
Scientific Programme, Keynote lectures

SPEAKER:
Barbara Rath, Vienna Vaccine Safety Initiative

Sunday 6 December, 14:00 - 16:00 CET
Viral and host factors in the transmission of influenza, RSV disease and COVID-19, including genomics and big data

SCS

TIME:
Sunday 6 December, 14:00 - 16:00 CET

TRACK:
Scientific Programme

CHAIRS:
Ron Fouchier, Erasmus MC Rotterdam
Maria Auladel, University of Melbourne

- PROGRAMME:
1. **Influenza viruses with reduced baloxavir susceptibility demonstrate lower fitness in ferrets**
Leo Yi Yang Lee, WHO Collaborating Centre for Reference and Research on Influenza, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia
 2. **The relationship between viral shedding in nose, throat and exhaled breath and symptom severity of respiratory viruses**
Nancy H. L. Leung, WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong
 3. **N-glycolyneuraminic acid-binding of H7 Influenza A viruses**
Cindy M. Spruijt, Department of Chemical Biology & Drug Discovery, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, 3584 CG Utrecht, The Netherlands
 4. **Novel model to determine how influenza viral shedding correlates with infectiousness and to predict the impact of antivirals on reduction of influenza transmission**
Jason Asher, Leidos, Reston, Virginia, USA

Sunday 6 December, 14:00 - 16:00 CET
Epidemiology, surveillance and modeling of influenza, RSV disease and COVID-19, including virus evolution and strain selection

SCS

TIME:
 Sunday 6 December, 14:00 - 16:00 CET

TRACK:
 Scientific Programme

CHAIRS:
 Colin Russell, Academic Medical Center, University of Amsterdam
 Bingyi Yang, The University of Hong Kong

- PROGRAMME:
- 1. Mapping the global antigenic diversity of avian H7 influenza A viruses**
 Adinda Kok, Department of Viroscience, Postgraduate School Molecular Medicine, Erasmus MC, Rotterdam, The Netherlands
 - 2. National influenza surveillance systems in five European countries: a comparative framework based on WHO guidance**
 Thierry Rigoine de Fougerolles, Corporate Value Associates, France
 - 3. Evolution of receptor specificity of contemporary A/H3N2 explains inability to agglutinate erythrocytes**
 Frederik Broszeit, Utrecht University, The Netherlands
 - 4. Difference in the age and gender distribution of Covid-19 cases following movement restriction measures in Asia**
 Damien Alain Michel Phillippon, WHO Collaborating Center for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China
 - 5. Evaluating virus interference in a trial of influenza vaccination in children**
 Tim K. Tsang, WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China.

Sunday 6 December, 15:00 - 16:00 CET
Poster Peek with Marco Goeijenbier

LIVE ↕

TIME:
 Sunday 6 December, 15:00 - 16:00 CET

Marco Goeijenbier discusses trending posters.

Sunday 6 December, 16:00 - 18:00 CET
Satellite symposium organised by Seqirus: Strengthening influenza protection: Different needs, different solutions

SAT

LIVE ↕

TIME:
 Sunday 6 December, 16:00 - 18:00 CET

TRACK:
 Satellite sessions

CHAIR:
 Joan Puig-Barberà, Foundation for the Promotion of Health and Biomedical Research of the Valencian Community (FISABIO)

- PROGRAMME:
- 1. Protecting a diverse population**
 Joan Puig-Barberà, Foundation for the Promotion of Health and Biomedical Research of the Valencian Community (FISABIO), Spain
 - 2. Safeguarding the older generation**
 Caterina Rizzo, Bambino Gesù Pediatric Hospital, Italy
 - 3. Shielding special populations**
 Catherine Moore, Public Health Wales, United Kingdom
 - 4. Preparing for an influenza pandemic - and what we can learn from SARS-CoV-2**
 Florian Kramer, Icahn School of Medicine at Mount Sinai, United States of America
 - 5. Panel and audience discussion**
 Joan Puig-Barberà, Foundation for the Promotion of Health and Biomedical Research of the Valencian Community (FISABIO), Spain
 - 6. Closing remarks**
 Joan Puig-Barberà, Foundation for the Promotion of Health and Biomedical Research of the Valencian Community (FISABIO), Spain

Sunday 6 December, 18:00 - 20:00 CET
Special keynote lecture Janssen: Janssen's efforts in the development of a COVID-19 vaccine

KEY

TIME:
 Sunday 6 December, 18:00 - 20:00 CET

TRACK:
 Keynote lectures

SPEAKER:
 Hanneke Schuitemaker, Janssen

Sunday 6 December, 18:00 - 20:00 CET
Virus structure and replication in influenza virus, RSV and SARS-CoV-2; latest developments in influenza virus, SARS-CoV-2 and RSV molecular virology

SCS

TIME:
 Sunday 6 December, 18:00 - 20:00 CET

TRACK:
 Scientific Programme

CHAIRS:
 Ervin Fodor, University of Oxford
 Aitor Nogales, National Institute for Agricultural and Food Research and Technology (INIA)

- PROGRAMME:
- 1. Upstream translation initiation expands the coding capacity of influenza viruses**
 Lea Meyer, MRC-University of Glasgow Centre for Virus Research, Glasgow G61 1QH, UK
 - 2. Optimized reverse genetics systems for clinical isolates of respiratory syncytial virus enables rapid evaluation of naturally occurring antibody escape mutants**
 Allina Schadenhofer, Research Center for Emerging Infections and Zoonoses, University of Veterinary Medicine Hannover, Germany
 - 3. Homologous PB2-HA packaging signals direct influenza A virus reassortment**
 Courtney L. Steger, Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA, USA
 - 4. Alternative splicing liberates a cryptic cytoplasmic isoform of mitochondrial MECR that antagonizes influenza virus**
 Steven F. Baker, Department of Medical Microbiology and Immunology, University of Wisconsin-Madison, United States of America
 - 5. Host ANP32A mediates the assembly of the influenza virus replicase**
 Haitian Fan, Sir William Dunn School of Pathology, University of Oxford, South Parks Road, Oxford OX1 3RE, United Kingdom

Sunday 6 December, 18:00 - 20:00 CET
Benefits of vaccination of healthcare workers

SPI

TIME:
 Sunday 6 December, 18:00 - 20:00 CET

TRACK:
 Science Policy Interface

CHAIR:
 Hanna Nohynek, Finnish Institute for Health and Welfare

- PROGRAMME:
- 1. Annual seasonal influenza vaccination of health care workers**
 Rebecca Cox, University of Bergen, Norway
 - 2. Mandatory vaccination for healthcare workers in the US**
 Litjen Tan, National Adult Immunization Summit and National Influenza Vaccine Summit, United States of America
 - 3. Current recommendations and guidelines for healthcare workers vaccination: an overview**
 Ted van Essen, General Practice, The Netherlands
 - 4. The ethics of influenza vaccination of healthcare workers: a critical appraisal**
 Sarah Edwards, University College London, United Kingdom

Sunday 6 December, 20:00 - 22:00 CET

Satellite symposium organised by AstraZeneca: Targeting SARS-CoV-2: Novel vaccines and antivirals for the prevention and treatment of COVID-19

SAT

TIME:

Sunday 6 December, 20:00 - 22:00 CET

LIVE 

TRACK:

Satellite sessions

Veeva ID: Z4-27960

PROGRAMME:

1. **Chair's introduction**

Jorge Flores, PATH, United States of America

2. **New advances in COVID-19 vaccine development**

Sarah Gilbert, University of Oxford, United Kingdom

3. **Exploring new therapies for COVID-19: Focus on monoclonal antibodies**

Mark Esser, AstraZeneca, United States of America

4. **Q&A panel**

Jorge Flores, PATH, United States of America

Sunday 6 December, 22:00 - 22:30 CET

Recap of the day: Highlights with Colin Russell and Brooke Nichols

TIME:

Sunday 6 December, 22:00 - 22:30 CET

LIVE 

Monday 7 december

Monday 7 December, 08:00 - 08:30 CET

Morning welcome lecture: Antiviral and Immune Modifiers for Treatment of Influenza, RSV and COVID-19

KEY

TIME:


Monday 7 December, 08:00 - 08:30 CET

TRACK:

Keynote lectures

SPEAKER:

Michael Ison, Northwestern University

supported by 

Monday 7 December, 08:00 - 10:00 CET

Webinar: Clinical manifestations of Influenza, RSV and COVID-19

TIME:

Monday 7 December, 08:00 - 10:00 CET

CHAIR:

Ab Osterhaus, TIHo, Hannover

1. Clinical signs and symptoms: overlap and differences
Barbara Rath, Vienna Vaccine Safety Initiative, DE
2. Risk groups: overlap and difference
Daniel Feikin, World Health Organisation, CH
3. Clinical guidelines and symptomatic treatment
Peter Openshaw, Imperial College London, UK
4. Co-Infections: Possible scenarios
Bruno Lina, Université de Lyon, FR

Monday 7 December, 09:00 - 09:15 CET

Good morning with Colin Russell

TIME:

Monday 7 December, 09:00 - 09:15 CET

LIVE 

Monday 7 December, 10:00 - 12:00 CET

Satellite symposium organised by the Influenza Diabetes Community, supported by Sanofi Pasteur: Influenza in persons living with diabetes. Pathogenesis and prevention

SAT

TIME:

Monday 7 December, 10:00 - 12:00 CET

LIVE 

TRACK:

Satellite sessions

CHAIRS:

Marco Goeijenbier, Erasmus MC

Francesc Xavier Cos, Primary Care Diabetes Europe/ Institut Català de la salut

PROGRAMME:

- The impact of influenza on people with diabetes**
Marco Goeijenbier, Erasmus MC, The Netherlands
- Influenza vaccination and people with diabetes: a must !**
Francesc Xavier Cos, Primary Care Diabetes Europe/ Institut Català de la salut, Spain
- Recent findings in glycemic variability and influenza severity**
Kirsty Short, University of Queensland, Australia
- How to increase vaccination coverage in people with diabetes, the UK case**
Dan Howarth, Diabetes UK, United Kingdom
- Diabetes during the COVID-19 pandemic**
Ab Osterhaus, TIHO, Hannover, Germany

Monday 7 December, 12:00 - 12:30 CET

Special keynote lecture Janssen: Immunology underpinning vaccine strategy in COVID-19

KEY

TIME:

Monday 7 December, 12:00 - 12:30 CET

TRACK:

Keynote lectures

SPEAKER:

Peter Openshaw, Imperial College London

Monday 7 December, 12:00 - 12:30 CET

Keynote lecture: SARS-CoV2 : the hamster infection model, developing antiviral strategies and a unique single dose vaccine based on the yellow fever vaccine

KEY

TIME:

Monday 7 December, 12:00 - 12:30 CET

TRACK:

Keynote lectures

SPEAKER:

Johan Neyts, University of Leuven

Monday 7 December, 12:00 - 13:00 CET

Poster Peek with Brooke NicholsLIVE 

TIME:

Monday 7 December, 12:00 - 13:00 CET

Colin Russell discusses trending posters.

Monday 7 December, 12:00 - 14:00 CET

All you need to know about influenza, RSV disease and COVID-19

SPI

TIME:

Monday 7 December, 12:00 - 14:00 CET

TRACK:

Science Policy Interface

CHAIR:

Ab Osterhaus, TIHO, Hannover

PROGRAMME:

- Impact of Influenza Vaccination on Antibiotic Use and Antimicrobial Resistance: a Mixed Methods Study to Develop a Strategic Plan**
Lotte van Heuvel, Nivel, Netherlands Institute for Health Services Research, The Netherlands
- All you need to know about influenza, both epidemic and pandemic**
Ab Osterhaus, TIHO, Hannover, Germany
- All you need to know about RSV disease**
Terho Heikkinen, University of Turku, Finland
- COVID-19 Vaccine Development and Approvals in the US: Operation Warp Speed**
Arnold Monto, University of Michigan, United States of America
- How viruses travel tricky routes**
Colin Russell, Academic Medical Center, University of Amsterdam, The Netherlands

Monday 7 December, 14:00 - 16:00 CET

Satellite symposium organised by Janssen: Addressing the ever-changing burden of RSV: The past, present and post COVID-19

SAT

TIME:

Monday 7 December, 14:00 - 16:00 CET

LIVE 

TRACK:

Satellite sessions

CHAIR:

Peter Openshaw, Imperial College London

PROGRAMME:

- Welcome and Introduction**
Peter Openshaw, Imperial College London, United Kingdom
- New insights into the full burden of RSV infection in children**
Terho Heikkinen, University of Turku, Finland
- Overcoming the identity crisis of RSV in adults: An under-recognised burden in at-risk populations**
Edward Walsh, Rochester General Hospital, United Kingdom
- Planning for a post-Covid-19 world: Can we expect large RSV outbreaks in 2021/2022?**
Peter Openshaw, Imperial College London, United Kingdom
- Panel Discussion**
Peter Openshaw, Imperial College London, United Kingdom
- Meeting close**
Peter Openshaw, Imperial College London, United Kingdom

Monday 7 December, 16:00 - 16:30 CET

Keynote lecture: RNA Structure in Influenza and Coronaviruses: A Comparison

KEY

TIME:

Monday 7 December, 16:00 - 16:30 CET

TRACK:

Keynote lectures

SPEAKER:

David LV Bauer, The Francis Crick Institute

Monday 7 December, 16:00 - 18:00 CET

Virial and host factors in the pathogenesis of influenza, RSV disease and COVID-19, including genomics and big data

SCS

TIME:

Monday 7 December, 16:00 - 18:00 CET

TRACK:

Scientific Programme

CHAIRS:

Barney Graham, Vaccine Research Center, NIAID, NIH
Kirsty Short, University of Queensland

PROGRAMME:

- Cellular importin- α 3 expression dynamics in the lung regulate antiviral response pathways against influenza A virus infection**
Sebastian Beck, Viral Zoonosis – One Health, Heinrich Pette Institute, Leibniz Institute for Experimental Virology, Hamburg, Germany
- Adaptation of an HPAI H5N1 virus to the ferret central nervous system?**
Jurrie Y. Slegers, Dept. of Viroscience, Erasmus MC, Rotterdam, the Netherlands
- Comparative genomics and transcriptomics help unravel why Australian Black Swans are uniquely susceptible to highly pathogenic avian influenza (HPAI)**
Anjana Karawita, School of Chemistry and Molecular Biosciences, The University of Queensland, Australia; Australian Centre for Disease Preparedness Services, CSIRO, Geelong, Australia
- Species-specific endotherotropism of Highly Pathogenic Avian Influenza Virus in avian hosts**
Anja C.M. de Bruijn, Department of Viroscience, Erasmus Postgraduate School Molecular Medicine, Erasmus MC, Rotterdam, The Netherlands
- Female-biased vaccine-induced immunity and protection against influenza A viruses is maintained against drifted and viruses in mice**
Rebecca Ursin, Johns Hopkins University Bloomberg School of Public Health, Department of Biochemistry and Molecular Biology, Baltimore, MD, USA

Monday 7 December, 16:00 - 18:00 CET

Reservoirs for future pandemics: threats from the animal world

SCS

TIME:

Monday 7 December, 16:00 - 18:00 CET

TRACK:

Scientific Programme

CHAIRS:

Ab Osterhaus, TiHo, Hannover
Guha Asthagiri Arunkumar, Icahn School of Medicine at Mount Sinai

PROGRAMME:

- Co-infections with low and high pathogenic avian influenza H5N8 virus demonstrate that HPAIV are more likely to emerge in chickens than in ducks**
Pierre Bessiere, Université de Toulouse, INRAE-ENVT, France
- Antigenic characterization of novel H1 influenza A viruses in swine**
Rodrigo Tapia, Departamento de Medicina Preventiva Animal, Facultad de Ciencias Veterinarias y Pecuarias, Universidad de Chile, Santiago, Chile.
- Characterizing the Functionality of the Wuhan Spiny Eel Influenza Virus Surface Glycoproteins**
Guha Asthagiri Arunkumar, Dept of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA
- Influenza D virus: a potential threat for humans?**
Claudia Trombetta, University of Siena, Italy

Monday 7 December, 16:00 - 18:00 CET

Influenza, RSV disease and COVID-19 intervention strategies: current practice and future strategies

SPI

TIME:

Monday 7 December, 16:00 - 18:00 CET

TRACK:

Science Policy Interface

CHAIR:

Menno de Jong, University of Amsterdam

PROGRAMME:

- Suppressing COVID-19 transmission in three epidemic waves in Hong Kong**
Peng Wu, WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong S.A.R. (China)
- Pre-pandemic and pandemic vaccines**
Florian Krammer, Icahn School of Medicine at Mount Sinai, United States of America
- Antivirals influenza, RSV, COVID-19: key recent developments**
Frederick Hayden, Professor Emeritus of Medicine, United States of America
- Non medical interventions**
Angeliki Melidou, European Centre for Disease Prevention and Control, Sweden
- Regulatory requirements of (pre)pandemic vaccines**
Marco Cavaleri, European Medicines Agency, The Netherlands

Monday 7 December, 18:00 - 18:30 CET

Special keynote lecture Cidara Therapeutics: Beyond Vaccines and mAbs: Progress Towards Universal Influenza Protection with Cloudbreak® Influenza Antiviral Conjugates (AVCs)

KEY

TIME:

Monday 7 December, 18:00 - 18:30 CET

TRACK:

Keynote lectures

PROGRAMME:

- Opening remarks**
Michael Grundel Ison, Northwestern University, United States of America
- Beyond Vaccines and mAbs: Progress Towards Universal Influenza Protection with Cloudbreak® Influenza Antiviral Conjugates (AVCs)**
Leslie Tari, Cidara Therapeutics, United States of America

Monday 7 December, 18:00 - 18:30 CET

Meet Colin Russell and Marco Goeijenbier in the lounge

TIME:

Monday 7 December, 18:00 - 18:30 CET

LIVE 

Monday 7 December, 18:00 - 20:00 CET
Innate and adaptive immune responses in influenza, RSV disease and COVID-19

SCS

TIME:
 Monday 7 December, 18:00 - 20:00 CET

TRACK:
 Scientific Programme

CHAIRS:
 Giuseppe Sautto, University of Georgia
 Guus Rimmelzwaan, University of Veterinary Medicine Hannover, Foundation

- PROGRAMME:
- In-concert immune dynamics during natural influenza virus infection and recovery in acute hospitalized patients**
 Thi H. O. Nguyen, Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Parkville 3010, Victoria, Australia
 - Integrated immune dynamics define correlates of COVID-19 severity and antibody responses**
 LC Rowntree, Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia; Co-first
 - Suboptimal SARS-CoV-2-specific CD8+ T-cell response associated with the prominent HLA-A*02:01 phenotype**
 Jennifer R Habel, Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria 3000, Australia
 - Molecular and functional dissection of the influenza virus-specific CD8+ T cell receptor repertoire during aging**
 CE van de Sandt, Dept. Microbiology and Immunology, The University of Melbourne at The Peter Doherty Institute, Melbourne, Australia; Dept. Hematopoiesis, Sanquin Blood Supply Foundation, Amsterdam, The Netherlands; Sanquin Blood Supply Foundation, Amsterdam, The Netherlands
 - A history of obesity increases the severity of influenza virus infection and the pro-inflammatory response of pulmonary leukocytes**
 Ellesandra C. Noye, School of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia Queensland 4072, Australia

Monday 7 December, 18:00 - 20:00 CET
Influenza, RSV disease and COVID-19 from a global health perspective, including underserved communities

SPI

TIME:
 Monday 7 December, 18:00 - 20:00 CET

TRACK:
 Science Policy Interface

CHAIR:
 Marta Nunes, University of the Witwatersrand

- PROGRAMME:
- PEDSIDEA_Community: Real-time Mapping of Influenza/RSV/COVID Incidence & Severity in Underserved Communities in the United States**
 Barbara Rath, Vienna Vaccine Safety Initiative, Germany
 - What is the impact of COVID-19 in underserved communities?**
 Olivia Trulloch, Anthrologica, United Kingdom
 - Unique features of the epidemiology of influenza and COVID-19 in low and middle-income countries – implications for policy**
 Cheryl Cohen, University of the Witwatersrand, South Africa
 - Global access to vaccines for LMIC- challenges and opportunities**
 Niteen Wairagkar, Vaccines for All, United States of America

Monday 7 December, 20:00 - 20:30 CET
Recap of the day: Highlights with Colin Russell and Ab Osterhaus

LIVE

TIME:
 Monday 7 December, 20:00 - 20:30 CET

Tuesday 8 december

Tuesday 8 December, 08:00 - 08:30 CET
Morning welcome lecture: Host cell factors that impact the emergence of pandemic respiratory viruses

KEY

TIME:
 Tuesday 8 December, 08:00 - 08:30 CET

TRACK:
 Keynote lectures

SPEAKER:
 Wendy Barclay, Imperial College London



Tuesday 8 December, 08:00 - 10:00 CET
Webinar: Intervention strategies for COVID-19, influenza and RSV

TIME:
 Tuesday 8 December, 08:00 - 10:00 CET

CHAIR:
 Ab Osterhaus, TIHo, Hannover

- Current strategies
Ab Osterhaus, RIZ, Hannover, Germany
- Testing and testing consequences
Chantal Reusken, RIVM, The Netherlands
- Influenza vaccination during COVID-19
Florian Krammer, Icahn School of Medicine, USA
- Antivirals & Biological Response Modifiers
Mike Ison, Northwestern University, USA

Tuesday 8 December, 09:00 - 09:15 CET
Good morning with Brooke Nichols

LIVE

TIME:
 Tuesday 8 December, 09:00 - 09:15 CET

Tuesday 8 December, 09:00 - 09:30 CET
Meet the expert (sponsored by Roche): Strategies to Reduce Influenza Transmission – limited availability, registration required

KEY

TIME:
Tuesday 8 December, 09:00 - 09:30 CET

TRACK:
Keynote lectures

SPEAKERS:
Andreas Widmer, University of Basel
Leo Yi Yang Lee, Peter Doherty Institute for Infection and Immunity



Tuesday 8 December, 10:00 - 10:30 CET
Keynote lecture: COVID-19 vaccine development: where are we?

KEY

TIME:
Tuesday 8 December, 10:00 - 10:30 CET

TRACK:
Keynote lectures

SPEAKER:
Melanie Saville, CEPI

Tuesday 8 December, 10:00 - 12:00 CET
Influenza, RSV disease and COVID-19: clinical impact and diagnostic approaches (including disease management in primary healthcare and hospital settings)

SCS

TIME:
Tuesday 8 December, 10:00 - 12:00 CET

TRACK:
Scientific Programme

CHAIRS:
Marco Goeyenbier, Erasmus MC
Tristan Clark, University of Southampton

- PROGRAMME:
- Clinical Impact of Molecular Point-of-Care Testing for COVID-19 in Adults Presenting to Hospital: A Prospective, Interventional, Non-Randomised, Controlled Study (CoV-19POC)**
Nathan J Brendish, School of Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK; Department of Infection, University Hospital Southampton NHS Foundation Trust, Southampton, UK
 - Impact of a routine molecular point-of-care 'test and treat' strategy for influenza in hospitalised adults: a multi-centre, randomised controlled trial (FluPOC)**
Tristan W Clark, School of Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK; Department of Infection, University Hospital Southampton NHS Foundation Trust, Southampton, UK; NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK; NIHR Post Doctoral Fellowship Programme, UK
 - Global Study of Adults Hospitalized with Influenza, Respiratory Syncytial Virus (RSV) and Human Metapneumonovirus (hMPV): Risk Factors, Clinical Characteristics and Outcomes**
Ann Falsey, Rochester General Hospital, University Of Rochester School Of Medicine
 - Pooled nasal and throat swabs, nasal swabs and saliva as alternative clinical specimens for the diagnosis of COVID-19: a systematic review and meta-analysis**
Ngai Yung Tsang, WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR.
 - Lethal and not-so-lethal mutagenesis: Changes in fitness and mutation rate during the treatment of respiratory syncytial virus with ribavirin and favipiravir**
Chris Illingworth, University of Cambridge, United Kingdom

Tuesday 8 December, 10:00 - 12:00 CET
Young Scientists at work

SCS

TIME:
Tuesday 8 December, 10:00 - 12:00 CET

TRACK:
Scientific Programme

CHAIRS:
Ab Osterhaus, TiHo, Hannover
Gülsah Gabriel, Heinrich Pette Institute

- PROGRAMME:
- Announcement Best Body of Work Award**
Ab Osterhaus, TiHo, Hannover, Germany
 - Understanding influenza A virus receptor specificity is essential for vaccine development**
Robert de Vries, Utrecht University, The Netherlands
 - Announcement of the Innovative Award**
Russell Bassler, Seqirus, United States of America
 - Metabolic disease and COVID-19**
Kirsty Short, University of Queensland, Australia
 - Dynamics of human life-course antibody profiles to influenza A (H3N2)**
Bingyi Yang, The University of Hong Kong, Hong Kong S.A.R. (China)
 - Influenza virus infection history drives and shapes antibody and B cell responses to seasonal influenza vaccination**
Maria Auladell, University of Melbourne, Australia

Tuesday 8 December, 12:00 - 14:00 CET
Satellite symposium organised by BioNTech: The Road to COVID-19 Vaccine Development

SAT

TIME:
Tuesday 8 December, 12:00 - 14:00 CET

TRACK:
Satellite sessions

- PROGRAMME:
- Welcome Address**
David Heymann, LSHTM, United Kingdom
 - Accelerated Development: How COVID-19 Vaccines are Being Developed Safely in Record Time**
Pieter Neels, Vaccine Advice BV, Belgium
 - Platforms to Launch: The Cutting-Edge Technologies Underpinning COVID-19 Vaccines in Development**
Drew Weissman, University of Pennsylvania, United States of America
 - Latest Data and Insights: COVID-19 Vaccine Candidates**
Robert French, Cincinnati Childrens Hospital, United States of America
 - Panel Q&A**
David Heymann, LSHTM, United Kingdom
 - Multidisciplinary Discussion What Happens Next? Approaching Vaccination in a Post-Pandemic World**
David Heymann, LSHTM, United Kingdom
 - Final Summary & Close**
David Heymann, LSHTM, United Kingdom

Tuesday 8 December, 14:00 - 14:30 CET
Keynote lecture: Long-distance airborne dispersal of SARS-CoV-2 in COVID-19 wards

KEY

TIME:
Tuesday 8 December, 14:00 - 14:30 CET

TRACK:
Keynote lectures

SPEAKER:
Janina Krambrich, Uppsala University

Tuesday 8 December, 14:00 - 15:00 CET
Poster Peek with Colin Russell

TIME:
 Tuesday 8 December, 14:00 - 15:00 CET

LIVE ↕

Marco Goeijenbier discusses trending posters.

Tuesday 8 December, 14:00 - 16:00 CET
Threats and risk management of epidemics and pandemics

SCS

TIME:
 Tuesday 8 December, 14:00 - 16:00 CET

TRACK:
 Scientific Programme

CHAIRS:
 Colin Russell, Academic Medical Center, University of Amsterdam
 Ann Moen, World Health Organization

- PROGRAMME:
- Avian H5 influenza A viruses: towards antigen design of a universal H5 vaccine**
 Mathilde Richard, Department of Viroscience, ErasmusMC, The Netherlands
 - A meta-analysis on the role of children in SARS-CoV-2 in household transmission clusters**
 Yanshan Zhu, School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane Australia
 - Rapid global SARS-CoV-2 external quality assurance (EQA) programme by influenza mechanism of the Global Influenza Surveillance and Response System (GISRS)**
 Dmitry Pereyaslov, World Health Organization, Switzerland
 - Social contact patterns and age dependent susceptibility shape the re-emergence potential of A/H3N2 influenza viruses**
 Joseph Gibson, Amsterdam University Medical Center, The Netherlands

Tuesday 8 December, 14:00 - 16:00 CET
Influenza, RSV disease and COVID-19 vaccination: current and future approaches

SCS

TIME:
 Tuesday 8 December, 14:00 - 16:00 CET

TRACK:
 Scientific Programme

CHAIRS:
 Barney Graham, Vaccine Research Center, NIAID, NIH
 Miruna Elena Rosu, Erasmus Medical Center

- PROGRAMME:
- Detailed analysis of the immune response after ChAdOx1 nCoV-19 vaccination**
 Teresa Lambie, Jenner Institute, Nuffield Department of Medicine, University of Oxford, United Kingdom
 - Conserved hemagglutinin stem immunogens elicit cross-group protective broadly neutralizing antibody responses to influenza A viruses**
 Syed Moïn, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
 - Potent protective immunity to influenza by HA nanoparticle vaccines**
 Seyhan Boyoglu-Barnum, NIH, United States of America
 - Structure-based design of stabilized recombinant influenza neuraminidase tetramers**
 Julia Lederhofer, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, United States
 - AS03-adjuvanted recombinant SARS-CoV-2 S antigen vaccine candidate: from non-clinical to clinical development**
 Valerie Lecouturier, Sanofi Pasteur, Marcy l'etoile, France

Tuesday 8 December, 14:00 - 16:00 CET
Antiviral and immune therapy for influenza, RSV disease and COVID-19

SCS

TIME:
 Tuesday 8 December, 14:00 - 16:00 CET

TRACK:
 Scientific Programme

CHAIRS:
 Frederick Hayden, Professor Emeritus of Medicine
 Joanne Mckenzie, University of Sheffield

- PROGRAMME:
- Combining baloxavir with standard-of-care (SoC) neuraminidase inhibitor (NAI) in patients hospitalised with severe influenza: results from the global randomised phase 3 FLAGSTONE study**
 Deepali Kumar, University Health Network, Toronto, Ontario, Canada
 - Structural and functional characterization of a SARS-CoV-1 and -2 cross-neutralizing single domain antibody and their clinical potential**
 Xavier Saelens, Ghent University and VIB, Belgium
 - Treatment-Emergent Resistance to the Influenza Antiviral Baloxavir: Pooled Analysis of Baloxavir Clinical Trials**
 Jimmie Ko, Genentech, Inc., South San Francisco, CA, United States of America
 - Characterization of In Vitro Activity and In Vivo Efficacy of CD377, a Novel Anti-Viral Fc-Conjugate, Against 2020-2021 Northern Hemisphere Influenza Quadrivalent Vaccine Strains**
 Jeffrey Locke, Cidara Therapeutics, United States of America

Tuesday 8 December, 16:00 - 18:00 CET
Satellite symposium organised by Roche: Can we stop flu going viral?

SAT

TIME:
 Tuesday 8 December, 16:00 - 18:00 CET

LIVE ↕

TRACK:
 Satellite sessions

CHAIR:
 Frederick Hayden, Professor Emeritus of Medicine

- PROGRAMME:
- Welcome and introduction**
 Frederick Hayden, Professor Emeritus of Medicine, United States of America
 - Antiviral treatment in hospitalised patients: Setting the scene**
 Frederick Hayden, Professor Emeritus of Medicine, United States of America
 - Antiviral treatment in hospitalised patients**
 Jean-Paul Mira, Centre Hospitalier Paris Centre, France
 - Role of antiviral treatment in reducing the spread of influenza: Setting the scene**
 Frederick Hayden, Professor Emeritus of Medicine, United States of America
 - Role of antiviral treatment in reducing the spread of influenza**
 Lauren Meyers, The University of Texas at Austin, United States of America
 - Panel discussion with Jean-Paul Mira, Lauren Meyers, Menno de Jong, Deepali Kumar, Benjamin Cowling, Terho Heikkinen**
 Frederick Hayden, Professor Emeritus of Medicine, United States of America
 - Summary and closing remarks**
 Frederick Hayden, Professor Emeritus of Medicine, United States of America

Tuesday 8 December, 18:00 - 20:00 CET
Satellite symposium organised by Sanofi Pasteur: 10 years of evidence using high dose influenza vaccine in people age 65 and older

SAT

TIME:
Tuesday 8 December, 18:00 - 20:00 CET

LIVE 

TRACK:
Satellite sessions

CHAIR:
Rosalind Hollingsworth, Sanofi Pasteur

- PROGRAMME:
- 1. Opening remarks**
Rosalind Hollingsworth, Sanofi Pasteur, United States of America
 - 2. Burden of influenza diseases in people 65 years old and over**
Thomas Weinke, Klinikum Ernst von Bergmann, Germany
 - 3. High dose influenza vaccine: benefits for older adults**
Marc Van Ranst, University of Leuven, Belgium
 - 4. North America experience: high dose vaccine focus on long term care**
Stefan Gravenstein, Case Western Reserve University, United States of America
 - 5. Q&A and Closing Remarks with Thomas Weinke, Marc Van Ranst, Stefan Gravenstein**
Rosalind Hollingsworth, Sanofi Pasteur, United States of America

Tuesday 8 December, 20:00 - 20:30 CET
Recap of the day: Highlights with Colin Russell and Marco Goeijenbier

TIME:
Tuesday 8 December, 20:00 - 20:30 CET

LIVE 

Wednesday 9 december


Wednesday 9 December, 08:00 - 08:15 CET
Morning welcome lecture: Risk factors for severe outcomes following COVID-19 infection -results of a systematic literature review

KEY

TIME:
Wednesday 9 December, 08:00 - 08:15 CET

TRACK:
Keynote lectures

SPEAKER:
Pasi Penttinen, European Centre for Disease Prevention and Control (ECDC)

supported by 

Wednesday 9 December, 08:00 - 10:00 CET
Webinar: Cornerstones of pandemic preparedness and urgent actions

TIME:
Wednesday 9 December, 08:00 - 10:00 CET

CHAIR:
Ab Osterhaus, TIHO, Hannover

- 1. Vaccination**
Ab Osterhaus, RIZ, Hannover , Germany
Jonathan Anderson, Seqirus , Australia
- 2. Antivirals**
Frederick Hayden, University of Virginia , USA
- 3. Non-medical interventions**
Angeliki Melidou, ECDC , Sweden
- 4. Cross-sector collaboration and communication**
Sylvie Briand, World Health Organisation , Switzerland

Wednesday 9 December, 09:00 - 09:15 CET
Good morning with Marco Goeijenbier

TIME:
Wednesday 9 December, 09:00 - 09:15 CET

LIVE 

Wednesday 9 December, 09:00 - 09:30 CET

Meet the expert (sponsored by Roche): Management of Hospitalised Patients with Severe Influenza – limited availability, registration required

KEY

TIME:

Wednesday 9 December, 09:00 - 09:30 CET

TRACK:

Keynote lectures

SPEAKERS:

Tristan Clark, University of Southampton
Jean-Paul Mira, Centre Hospitalier Paris Centre



Wednesday 9 December, 10:00 - 12:00 CET

Satellite symposium organised by ESPID and ESWI. Should we introduce national live vaccination programmes for children?

SAT

TIME:

Wednesday 9 December, 10:00 - 12:00 CET

LIVE ↕

TRACK:

Satellite sessions

CHAIR:

Terho Heikkinen, University of Turku

AstraZeneca has provided a sponsorship grant towards this independent Programme

PROGRAMME:

- Why is influenza an important disease in children? An introduction.**
Terho Heikkinen, University of Turku, Finland
- Efficacy and safety of seasonal influenza vaccination in children**
Ab Osterhaus, TiHo, Hannover, Germany
- The burden of paediatric influenza in the US: mortality, hospitalizations, outpatient visits and other outcome**
Patsy Stinchfield, Children's Hospitals and Clinics of Minnesota, United States of America
- How to increase vaccine confidence and counter parental doubts on the safety and effectiveness of influenza vaccines?**
Hanna Nohynek, Finnish Institute for Health and Welfare, Finland
- Debate: should we introduce live vaccination programmes for children?**
Terho Heikkinen, University of Turku, Finland

Wednesday 9 December, 12:00 - 12:30 CET

Keynote lecture: Transmission dynamics and control of COVID-19: what have we learned so far?

KEY

TIME:

Wednesday 9 December, 12:00 - 12:30 CET

TRACK:

Keynote lectures

SPEAKER:

Neil Ferguson, Imperial College London

Wednesday 9 December, 12:00 - 13:00 CET

Poster Peek with Colin Russell

TIME:

Wednesday 9 December, 12:00 - 13:00 CET

LIVE ↕

Colin Russell discusses trending posters.

Wednesday 9 December, 12:00 - 14:00 CET

Animal influenza, ecology and epidemiology

SCS

TIME:

Wednesday 9 December, 12:00 - 14:00 CET

TRACK:

Scientific Programme

CHAIRS:

Malik Peiris, The University of Hong Kong
Rodrigo Tapia, Virbac-Centrovet

PROGRAMME:

- Transmission dynamics of avian influenza viruses along poultry value chains in Bangladesh: a controlled field experiment**
Lisa Kohnle, City University of Hong Kong, Hong Kong S.A.R. (China)
- In vivo and in vitro characterization of highly pathogenic influenza A virus (H5N8) neurotropism in duck and chicken.**
Thomas Figueroa, Université de Toulouse, ENVT, INRAE, UMR 1225, Toulouse, France
- Sentinel Birds as an Indicator of the Influenza Virus Presence in the Natural Environment**
Semen Tkachenko, National Scientific Center Institute of Experimental and Clinical Veterinary Medicine
- LPAIV Prevalence, Subtype Diversity and Migration Connectivity of Dabbling Duck the Azov-Black Sea Region in Ukraine**
Denys Muzyka, National Scientific Center Institute of Experimental and Clinical Veterinary Medicine, Kharkiv, Ukraine
- Case Report - A case comparison of early versus late detection and depopulation of two chicken farms infected with highly pathogenic avian influenza virus during the 2015 H5N2 outbreak**
Kaityn St. Charles, Secure Food Systems Team, University of Minnesota, College of Veterinary Medicine, United States of America

Wednesday 9 December, 12:00 - 14:00 CET

Influenza, RSV disease and COVID-19 vaccination: current and future approaches

SCS

TIME:

Wednesday 9 December, 12:00 - 14:00 CET

TRACK:

Scientific Programme

CHAIRS:

Peter Openshaw, Imperial College London
Dennis Lapuente, University Hospital Erlangen

PROGRAMME:

- Contribution of neuraminidase to the efficacy of seasonal split influenza vaccines in the ferret model**
Miruna E. Rosu, Department of Viroscience, Erasmus Medical Center, Rotterdam 3015 CE, the Netherlands
- Antigen modifications improve mRNA-based influenza virus vaccine efficacy in mice**
Alec W Freyn, Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029; Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029
- IL-1 β as mucosal vaccine adjuvant: Specific induction of tissue-resident memory T cells and enhanced protection against heterologous IAV**
Dennis Lapuente, Institute of Clinical and Molecular Virology, University Hospital Erlangen, Germany
- A comprehensive influenza reporter virus panel for decomposing polyclonal sera using neutralization maps**
Adrian Creanga, National Institute of Allergy and Infectious Diseases, United States of America
- CELL RESPONSE 2: Relative vaccine effectiveness against influenza-related hospitalizations and serious respiratory events during the 2018/19 influenza season in children and adults. Comparison between quadrivalent cell-based and egg-based influenza vaccines**
Joaquin Federico Mould-Quevedo, Seqirus Vaccines Ltd., Summit, NJ, USA

Wednesday 9 December, 14:00 - 14:30 CET
Keynote lecture: Vaccine confidence in a time of covid

KEY

TIME:
Wednesday 9 December, 14:00 - 14:30 CET

TRACK:
Keynote lectures

SPEAKER:
Heidi Larson, London School of Hygiene & Tropical Medicine

Wednesday 9 December, 14:00 - 16:00 CET
Co-infections in influenza, RSV disease and COVID-19

SCS

TIME:
Wednesday 9 December, 14:00 - 16:00 CET

TRACK:
Scientific Programme

CHAIR:
Ed Hutchinson, University of Glasgow

- PROGRAMME:
- The burden and clinical characteristics of viral respiratory disease before and during the SARS-CoV-2 pandemic**
Stephen Poole, NIHR Biomedical Research Centre Southampton, United Kingdom; University Hospitals Southampton NHS Trust
 - Evolution and selection of influenza a virus defective interfering particles in a semi-continuous production system for the use as antiviral**
Lars Pelz, Max-Planck Institute for Dynamics of Complex Technical Systems, Germany
 - Superinfection exclusion limits genome interactions during localised spread of influenza A viruses.**
Anna Sims, MRC-University of Glasgow Centre for Virus Research, United Kingdom
 - Aspergillosis Complicating Severe Influenza and Respiratory Syncytial Virus (RSV) in ICU Patients**
Hannah Hyochan Nam, University of California, Irvine, United States of America

Wednesday 9 December, 14:00 - 16:00 CET
Risk evaluation and communication strategies in influenza and COVID-19: lessons learned

SPI

TIME:
Wednesday 9 December, 14:00 - 16:00 CET

TRACK:
Science Policy Interface

CHAIR:
Pasi Penttinen, European Centre for Disease Prevention and Control (ECDC)

- PROGRAMME:
- Cross-sectoral collaboration and communication**
Tim Nguyen, World Health Organisation, Switzerland
 - The role of experts in guiding policy**
Peter Openshaw, Imperial College London, United Kingdom
 - Reaching out to people at risk – focus on the elderly: why and how,**
Janet McElhaney, Health Sciences North Research Institute, Canada; Northern Ontario School of Medicine, Canada
 - Talking vaccines is risky business: challenges in the post-trust environment**
Frederic Boudier, University of Stavanger, Norway

Wednesday 9 December, 14:00 - 16:00 CET
Burden of influenza, RSV disease and COVID-19 and impact on society

SPI

TIME:
Wednesday 9 December, 14:00 - 16:00 CET

TRACK:
Science Policy Interface

CHAIRS:
Rebecca Cox, University of Bergen
Kathy Sze Man Leung, The University of Hong Kong

- PROGRAMME:
- Mortality Associated with Seasonal Influenza Epidemics in the European Union: Overall Estimates based on Respiratory Mortality from 2002-2011**
John Paget, Nivel, Utrecht, the Netherlands
 - Excess Mortality and Healthcare Resource Use Attributed to Influenza in People at High Risk for Developing Complications: Real World Evidence from a US Managed Care Population**
Susan C. Bolge, Janssen Global Services, LLC, Raritan, USA
 - A Systematic Literature Review and a Meta-analysis of the Respiratory Syncytial Virus (RSV) Burden of Disease in Adults Over 60 Years of Age**
Miloje Savic, GSK, Wavre, Belgium
 - The disease burden of respiratory syncytial virus infection in young children in primary care: results from the RSV ComNet pilot in Italy and the Netherlands**
Jozanneke JGT van Summeren, Nivel, Netherlands Institute for Health Services Research, Utrecht, Netherlands, The

Wednesday 9 December, 16:00 - 18:00 CET
Late Breakers: novel and outstanding scientific discoveries

SCS

TIME:
Wednesday 9 December, 16:00 - 18:00 CET

TRACK:
Scientific Programme

CHAIR:
Murielle Ducatez, INRAE

- PROGRAMME:
- The SARS-CoV-2 and other human coronavirus spike proteins are fine-tuned towards temperature and proteases of the human airways**
Manon Laporte, KU Leuven, Rega Institute for Medical Research, Belgium
 - The avian-to-human adaptation of the 1968 A/H3N2 pandemic influenza virus**
Zandra Felix Garza, Department of Medical Microbiology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
 - Phase 1 trial Results of a Candidate Recombinant Virus-Like Particle Vaccine for Covid-19 Disease Produced in Plants and Adjuvanted with GSK's Pandemic Adjuvant**
Brian J. Ward, Medicago Inc., Canada; Research Institute of the McGill University Health Centre, Canada
 - The contrasting within-host evolutionary dynamics between seasonal and pandemic human influenza A viruses**
Alvin X. Han, Laboratory of Applied Evolutionary Biology, Department of Medical Microbiology, Amsterdam University Medical Center, Amsterdam, The Netherlands; Laboratory of Applied Evolutionary Biology, Department of Medical Microbiology, Amsterdam University Medical Center, Amsterdam, The Netherlands
 - Acute, Suprapharmacologic Dexamethasone Mobilizes Natural Killer T and Cytotoxic T cells for Influenza A/B-induced or COVID-19-induced ARDS**
Theresa Deisher, AVM Biotechnology, United States of America

Wednesday 9 December, 18:00 - 18:15 CET

Recap of the day: Highlights with Colin Russell, Marco Goeijenbier and Brooke Nichols

TIME:

Wednesday 9 December, 18:00 - 18:15 CET

LIVE

Wednesday 9 December, 18:15 - 19:00 CET

Closing ceremony

TIME:

Wednesday 9 December, 18:15 - 19:00 CET

LIVE

Proceedings of the conference will be Special Issue of Vaccine, Elsevier.



SPI

Separate report of the Science Policy Interface track is disseminated end of December 2020 and downloadable on the influenzaconference.org site.